Oestrogen and progesterone receptors in breast cancer: past, present and future
D M Barnes,
A M Hanby,
D M Barnes
Hedley Atkins/ICRF Breast Pathology Laboratory, Guy's Hospital, London, UK
Search for more papers by this authorA M Hanby
Hedley Atkins/ICRF Breast Pathology Laboratory, Guy's Hospital, London, UK
Search for more papers by this authorD M Barnes,
A M Hanby,
D M Barnes
Hedley Atkins/ICRF Breast Pathology Laboratory, Guy's Hospital, London, UK
Search for more papers by this authorA M Hanby
Hedley Atkins/ICRF Breast Pathology Laboratory, Guy's Hospital, London, UK
Search for more papers by this authorAddress for correspondence: Dr D M Barnes, Hedley Atkins/ICRF Breast Pathology Laboratory, 3rd Floor Thomas Guy House, Guy's Hospital, London SE1 9RT, UK. e-mail: [email protected]
References
- 1 Donne J. The Comparison. Elegy circa 1605; 8; 352.
- 2 Zafrani B, Aubriot M-H & Mouret E et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000; 37; 536–545.
- 3
Beatson GT.
On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.
Lancet
1896; ii; 104–107.
10.1016/S0140-6736(01)72307-0 Google Scholar
- 4 Jensen EV & Jacobsen HI. Fate of steroid estrogens in target tissues. In: G Pincus, EP Vollmer, eds. Biological Activities of Steroids in Relation to Cancer. New York: Academic Press, 1960: 161–168.
- 5 Jensen EV, Block GE & Smith S et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monograph 1971; 34; 55–70.
- 6 McGuire WL, Carbonne PP & Vollmer EP. Estrogen Receptors in Breast Cancer. New York: Raven Press, 1975.
- 7 Jensen EV & DeSombre ER. Steroid hormone binding and hormone receptors. In: JF Holland, E Frie, Rc Bast, DW Kufe, DL Morton, RR Weichselbaum, eds. Cancer Medicine, 3rd edn. Philadelphia: Lea and Febinger, 1993: 815–823.
- 8 Korenman SG & Dukes BA. Specific estrogen binding by the cytoplasm of human breast carcinoma. J. Clin. Endocrinol. Metab. 1970; 30; 639–645.
- 9 Barnes DM, Ribeiro GG & Skinner LG. Two methods for measurement of oestradiol-17β and progesterone receptors in human breast cancer and correlation with response to treatment. Eur. J. Cancer 1977; 13; 1133–1143.
- 10 Greene GL, Nolan C & Engler JP et al. Monoclonal antibodies to human estrogen receptor. Proc. Natl. Acad. Sci. USA 1980; 77; 5115–5119.
- 11 Estes PA, Suba EJ & Lawler-Heavner J et al. Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies. Biochemistry 1987; 26; 6250–6262.
- 12 Jensen EV, Green GL & DeSombre ER. The estrogen-receptor immuoassay in the prognosis and treatment of breast cancer. Lab. Manage. 1986; 24; 25–42.
- 13 King WJ, DeSombre ER, Jensen EV & Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumours. Cancer Res. 1985; 45; 293–304.
- 14 Snead DRJ, Bell JA & Dixon AR et al. Methodology of immunohistochemical detection of oestrogen receptor in human breast carcinoma in formalin-fixed paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 1993; 23; 233–238.
- 15 Skoog L, Rutqvist LE & Wilking N. Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta. Oncol. 1992; 31; 139–141.
- 16 Barnes DM, Harris WH, Smith P, Millis RR & Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br. J. Cancer 1996; 74; 1445–1451.
- 17 Koenders A & Thorpe SM. Standardisation of steroid hormone receptor assays in human breast cancer. I. Reproducibility of oestradiol and progesterone receptor assays. Eur. J. Cancer Clin. Oncol. 1983; 19; 1221–1229.
- 18 Romain S, Laine Bidron C, Martin PM & Magdelenat H. EORTC receptor study group report: steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. Eur. J. Cancer 1995; 31A; 411–417.
- 19 Rhodes A, Jasani B, Barnes DM, Bobrow LG & Miller KD. The reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: inter-laboratory variance in the sensitivity of detection and evaluation of scoring systems. J. Clin. Pathol. 2000; 53; 125–130.
- 20 Leake R, Barnes D & Pinder S et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol . J. Clin. Pathol. 2000; 53; 634–635.
- 21 Written on behalf of the Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research. Biological markers maintaining standards. Br. J. Cancer 2000; 82; 1627–1628.
- 22 Roylance R, Gorman P & Harris W et al. Comparative genomic hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999; 59; 1433–1436.
- 23
Soler AP,
Knudsen KA,
Salazar H,
Han AC &
Keshgegian AA.
P-cadherin expression in breast carcinoma indicates poor survival.
Cancer
1999; 86; 1263–1272.DOI: 10.1002/(sici)1097-0142(19991001)86:7<1263::aid-cncr23>3.0.co;2-2
10.1002/(sici)1097-0142(19991001)86:7<1263::aid-cncr23>3.0.co;2-2 CAS PubMed Web of Science® Google Scholar
- 24 Daniel CW, Strickland P & Friedmann Y. Expression and functional role of E- and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev. Biol. 1995; 169; 511–519.DOI: 10.1006/dbio.1995.1165
- 25 Sapino A, Macri L & Gugliotta P et al. Immunophenotypic propoerties and estrogen dependency of budding cell structures in the developing mouse mammary gland. Differentiation 1993; 55; 13–18.
- 26 Jensen EV, Block GE, Smith S, Kyser K & DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monograph. 1971; 34; 55.
- 27 Cole MP, Jones CTA & Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46,474. Br. J. Cancer 1971; 25; 270–275.
- 28 Patterson JS & Battersby LA. Tamoxifen: an overview of recent studies in the file of oncology. Cancer Treat. Rep. 1980; 64; 775–778.
- 29 Barnes DM, Millis RR, Beex LVAM, Thorpe SM & Leake RE. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur. J. Cancer 1998; 34; 1677–1682.DOI: 10.1016/s0959-8049(98)00149-x
- 30 Horwitz KB, McGuire WL & Pearson OH et al. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189; 726–727.
- 31 McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol. 1978; 5; 428–433.
- 32 EBCTC Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351; 1451–1467.DOI: 10.1016/s0140-6736(97)11423-4
- 33 Elledge RM & Osborne CK. Oestrogen receptors and breast cancer. Br. Med. J. 1997; 314; 1843–1844.
- 34 Howell A & Bush H. George WD et al. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for breast cancer. Lancet 1984; 2; 307–311.
- 35
Miles DW,
Harris WH,
Gillett CE,
Smith P &
Barnes DM.
The effect of c-erbB2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant CMF.
Int. J. Cancer
1999; 84; 354–359.DOI: 10.1002/(sici)1097-0215(19990820)84:4<354::aid-ijc4>3.0.co;2-6
10.1002/(sici)1097-0215(19990820)84:4<354::aid-ijc4>3.0.co;2-6 CAS PubMed Web of Science® Google Scholar
- 36 Beral V, Hermon C, Reeves G & Peto R. Sudden fall in breast cancer death rates in England and Wales. Lancet 1995; 345; 1642–1643.
- 37 Peto R, Boreham J, Clarke M, Davies C & Beral V. UK and USA breast cancer deaths down 25% in year at ages 20–69 years. The Lancet 2000; 355; 1822.DOI: 10.1016/s0140-6736(00)02277-7
- 38 Barnes DM & Miles DW. Response of metastatic breast cancer to trastuzumab? Lancet 2000; 355; 160–161.DOI: 10.1016/s0140-6736(99)00430-4
Citing Literature
